company background image
STXS

Stereotaxis NYSEAM:STXS Stock Report

Last Price

US$1.88

Market Cap

US$140.6m

7D

6.8%

1Y

-65.6%

Updated

04 Oct, 2022

Data

Company Financials +
STXS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

STXS Stock Overview

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.

Stereotaxis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stereotaxis
Historical stock prices
Current Share PriceUS$1.88
52 Week HighUS$7.22
52 Week LowUS$1.72
Beta1.69
1 Month Change-7.84%
3 Month Change-1.57%
1 Year Change-65.57%
3 Year Change-37.12%
5 Year Change79.05%
Change since IPO-97.60%

Recent News & Updates

Shareholder Returns

STXSUS Medical EquipmentUS Market
7D6.8%6.4%4.4%
1Y-65.6%-25.7%-18.2%

Return vs Industry: STXS underperformed the US Medical Equipment industry which returned -27.3% over the past year.

Return vs Market: STXS underperformed the US Market which returned -20% over the past year.

Price Volatility

Is STXS's price volatile compared to industry and market?
STXS volatility
STXS Average Weekly Movement10.7%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: STXS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: STXS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1990130David Fischelhttps://www.stereotaxis.com

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room.

Stereotaxis Fundamentals Summary

How do Stereotaxis's earnings and revenue compare to its market cap?
STXS fundamental statistics
Market CapUS$140.61m
Earnings (TTM)-US$18.54m
Revenue (TTM)US$30.54m

4.6x

P/S Ratio

-7.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STXS income statement (TTM)
RevenueUS$30.54m
Cost of RevenueUS$10.26m
Gross ProfitUS$20.28m
Other ExpensesUS$38.81m
Earnings-US$18.54m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin66.41%
Net Profit Margin-60.70%
Debt/Equity Ratio0%

How did STXS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is STXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STXS?

Other financial metrics that can be useful for relative valuation.

STXS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.9x
Enterprise Value/EBITDA-7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does STXS's PS Ratio compare to its peers?

STXS PS Ratio vs Peers
The above table shows the PS ratio for STXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.6x
TCMD Tactile Systems Technology
0.7x13.7%US$165.7m
OWLT Owlet
1.8x42.3%US$123.5m
AXDX Accelerate Diagnostics
11.9x19.9%US$158.5m
KRMD KORU Medical Systems
4x11.7%US$100.4m
STXS Stereotaxis
4.6x29.2%US$140.6m

Price-To-Sales vs Peers: STXS is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (4.6x).


Price to Earnings Ratio vs Industry

How does STXS's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: STXS is expensive based on its Price-To-Sales Ratio (4.6x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is STXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ratio6.2x

Price-To-Sales vs Fair Ratio: STXS is good value based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).


Share Price vs Fair Value

What is the Fair Price of STXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STXS's revenue (29.2% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: STXS's revenue (29.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STXS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Stereotaxis performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-26.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: STXS is currently unprofitable.

Growing Profit Margin: STXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STXS is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: STXS has a negative Return on Equity (-48.39%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Stereotaxis's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: STXS's short term assets ($46.6M) exceed its short term liabilities ($13.7M).

Long Term Liabilities: STXS's short term assets ($46.6M) exceed its long term liabilities ($7.5M).


Debt to Equity History and Analysis

Debt Level: STXS is debt free.

Reducing Debt: STXS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 0% each year


Discover healthy companies

Dividend

What is Stereotaxis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Stereotaxis Dividend Yield vs Market
How does Stereotaxis dividend yield compare to the market?
SegmentDividend Yield
Company (Stereotaxis)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.5%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (Stereotaxis)n/a

Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STXS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

David Fischel (35 yo)

6.08yrs

Tenure

US$57,459,868

Compensation

Dr. David Leo Fischel, CPA, CFA, CAIA, MBA, has been the Chairman and Chief Executive Officer of Stereotaxis, Inc. since February 3, 2017 and its Director since September 29, 2016. Dr. Fischel is a Princip...


CEO Compensation Analysis

David Fischel's Compensation vs Stereotaxis Earnings
How has David Fischel's remuneration changed compared to Stereotaxis's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$57mUS$60k

-US$12m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$321kUS$5k

-US$8m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$240kn/a

-US$6m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$59kn/a

-US$1m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$43kn/a

-US$7m

Sep 30 2017n/an/a

US$752k

Jun 30 2017n/an/a

-US$7m

Mar 31 2017n/an/a

-US$9m

Dec 31 2016US$28kn/a

-US$12m

Compensation vs Market: David's total compensation ($USD57.46M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: STXS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: STXS's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NYSEAM:STXS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 May 22BuyUS$25,967Arbiter Partners Capital Management, LLCCompany14,300US$1.85
24 May 22BuyUS$25,984Arbiter Partners Capital Management, LLCCompany14,292US$1.86
20 May 22BuyUS$77,725Arbiter Partners Capital Management, LLCCompany43,263US$1.80
18 May 22BuyUS$100,051Arbiter Partners Capital Management, LLCCompany55,025US$1.82
13 May 22BuyUS$287,082Arbiter Partners Capital Management, LLCCompany156,751US$1.88

Ownership Breakdown

What is the ownership structure of STXS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,952,9745.3%
Hedge Funds13,680,55418.3%
Institutions23,329,04631.2%
General Public33,827,50045.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 49.62% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.29%
Dafna Capital Management, LLC
13,680,554$25.7m0%6.4%
4.11%
Andrew Redleaf
3,076,923$5.8m0%no data
3.42%
Arbiter Partners Capital Management, LLC
2,554,583$4.8m12.49%3.89%
2.83%
The Vanguard Group, Inc.
2,116,616$4.0m-12.81%no data
2.81%
Opaleye Management Inc.
2,099,971$3.9m-12.34%1.46%
2.28%
Iron Triangle Partners LP
1,706,688$3.2m-0.31%0.5%
2.18%
Lagoda Investment Management, L.P.
1,630,040$3.1m32.53%1.93%
1.99%
Redmile Group, LLC
1,487,495$2.8m0%0.08%
1.37%
BlackRock, Inc.
1,022,412$1.9m-69.15%no data
1.2%
Millennium Management LLC
893,962$1.7m47.77%no data
1.07%
Renaissance Technologies LLC
798,100$1.5m1006.93%no data
1.07%
Rhenman & Partners Asset Management AB
797,330$1.5m0%0.15%
0.97%
Parian Global Management LP
724,924$1.4m19.37%7.9%
0.79%
Penn Capital Management Company, LLC
594,382$1.1m0%0.12%
0.67%
AlphaCentric Advisors LLC
500,000$940.0k25%0.91%
0.59%
Geode Capital Management, LLC
438,890$825.1k-45.56%no data
0.52%
Two Sigma Investments, LP
386,924$727.4k976.61%no data
0.5%
Two Sigma Advisers, LP
375,400$705.8k151.78%no data
0.49%
Silverarc Capital Management, LLC
368,648$693.1k6.42%0.29%
0.48%
David Benfer
361,631$679.9k4.49%no data
0.44%
Arun Menawat
329,285$619.1k0%no data
0.42%
Prescott Group Capital Management L.L.C.
317,460$596.8k0%0.11%
0.42%
Citadel Advisors LLC
314,428$591.1k178.95%no data
0.38%
Essex Investment Management Company, LLC
287,339$540.2k3.49%0.08%
0.33%
Jacobs Levy Equity Management Inc
245,198$461.0k0%no data

Company Information

Stereotaxis, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Stereotaxis, Inc.
  • Ticker: STXS
  • Exchange: NYSEAM
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$140.605m
  • Shares outstanding: 74.79m
  • Website: https://www.stereotaxis.com

Number of Employees


Location

  • Stereotaxis, Inc.
  • 710 North Tucker Boulevard
  • Suite 110
  • Saint Louis
  • Missouri
  • 63101
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STXSNYSEAM (NYSE MKT LLC)YesCommon SharesUSUSDAug 2004

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.